Eculizumab with trade name Soliris, is an FDA-approved drug to treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and neuromyelitis optica. Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Eculizumab specifically binds to the terminal complement component 5 or C5. Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.Anti-Eculizumab Antibody (13F5), mAb, mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with eculizumab.
- High specificity
- High affinity
- High stability
GenScript has developed a broad range of off-the-shelf anti-idiotype antibodies against blockbuster drugs to help accelerate your research of biosimilars.
Type:
Antigen: Eculizumab
Clonality: Monoclonal
Clone: 13F5
Conjugation: Unconjugated
Epitope:
Host: Mouse
Isotype: IgG1 kappa
Reactivity: